Reaction
Venture capitalSeed–Late Stage · 11 people tracked
Investment thesis
Reaction aims to drive exponential change by scaling innovations that improve lives and address urgent global problems. Its first fund, W250 Venture, backs proven leaders with world-changing potential in mission-aligned sectors such as health technology and climate innovation, and works to scale their innovations globally. Its second fund focuses on climate, globally scaling top Stanford climate innovations to accelerate progress toward net zero across the industries they can impact.
Source: firm website, verified Aug 3, 2026.
Team · 11 people
from the firm's website
What they invest in
from 2 of 2 portfolio companiesBiotech ×1Circular Economy ×1Climate Tech ×1GovTech ×1New Materials ×1
HQs:United States×2
Investments · 2 tracked
founders shown can be your intro path
Mango Materials develops biopolymers and biocomposites as sustainable alternatives to conventional plastics for consumer and industrial applications.
BiotechCircular EconomyClimate TechNew MaterialsVacaville, US
Frequently asked questions
- What stage does Reaction invest at?
- Reaction invests at the Seed, Series A, Late Stage stages.
- What sectors does Reaction focus on?
- Reaction focuses on Climate Tech, Healthtech, Impact & Social Good.
- Does Reaction lead rounds?
- Reaction typically participates in rounds rather than leading them.
Similar investors
500 Global (formerly 500 Startups) is a venture capital firm that invests in startups worldwide and runs programs for founders and investors.
Horizons Ventures is an investment firm focused on the deep science and technology community, backing early companies whose impact aims to overcome barriers to human potential.
Octopus Ventures is a founder-focused European venture capital firm that backs mission-driven startups across seven core sectors, investing from idea stage through growth with a focus on pre-seed to Series A.
Partech is a global investment firm that supports founders at every stage through dedicated teams and multiple funds across several continents.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.